Gilenya Sales

Quote












I read an article saying most of their business is coming from Copaxone and Avonex. Not really worried once BG12 comes out those patients will switch. Let them enjoy their one year of glory.
 


















May have 16000 Rx's written but then they need to get the pt on drug- conversion rates are low in many area's. No observation sites for Fed/State pts. Even trouble for commercial pts in many area's where offices have realized it's a loss to do observation in office.
 
























Anonymous said:
tysabri sales were down in Q4, and have heard whispers that they are also down in january. a lot of people are dropping off.
Click to expand...

Initially, Biogen stated that Ty gave MS patients a 67% reduction in the risk of exacerbations. Looked good in promo material.

But after a few years, that number has dropped to about 40% and the rate of PML continues to climb on a monthly basis even though the number of users are now flat.

No wonder sales are down and users are abandoning ship!
 
















































Anonymous said:
What does that have to do with another increase in PML cases??!! Woops, oh sorry...forgot that Biogen's marketing ignores dangerous side effects and attempts to change the focus of the problem by blaming something else.
Click to expand...

Novartis AG (NVS)' Gilenya Pill Loses Market Share as Doctors Become Wary

3/7/2012 8:15:22 AM

Novartis AG (NOVN)’s Gilenya multiple sclerosis pill lost market share for the first time in January, following the deaths of some patients soon after taking the first pill available for the disease in the U.S. Gilenya’s share of the U.S. market for so-called immunomodulatory drugs against MS fell to 6.1 percent from 6.2 percent in December, according to data from Wolters Kluwer NV (WKL), a market research company. The decline was the first after 15 months of growth, at a median of 15 percent a month, since the treatment received U.S. regulatory approval in September 2010.


Note date and time of this press release.....

what of the detailing of JC virus assay??? observations on impact on Ty use???
 






Both these drugs pose a devastating risk to MS patients....Tysabri's PML will kill you slowly or make you a vegetable and Gilenya will do you in very quickly!!

Both Novartis and Biogen minimize these dangers and market the drugs as though they are the answer to your MS problem.
 












Top Bottom
Back
Quote